DIRAS2

DIRAS2 is a Ras-related small GTPase that functions as a context-dependent suppressor of mitogenic signaling, controlling cell proliferation, autophagy, and neuronal excitability (PMID:29368982, PMID:38574733, PMID:41880562). Immediately after synthesis it forms a CAAX motif-dependent, high-affinity complex with SmgGDS that lowers its guanine nucleotide affinity and stabilizes the protein, rather than acting as a conventional nucleotide exchange factor (PMID:26149690). DIRAS2 abundance is tightly restrained by ubiquitin-dependent turnover: it is a substrate of the UBE2F-activated CRL5ASB11 E3 ligase complex (PMID:38574733), is ubiquitylated and degraded through interaction with the E3 ligase pVHL (PMID:32161311), and is degraded via the proteasome through interaction with the regulatory subunit PSMD2 (PMID:35173535); its expression is additionally silenced by promoter heterochromatinization and restored by HDAC inhibition (PMID:34680261), and is downregulated by STAT3 activation downstream of the eNAMPT/CCR5 axis (PMID:40083697). When stabilized and active, DIRAS2 suppresses RAS/MAPK and AKT1-MTOR signaling, driving FOXO3 and TFEB nuclear translocation to induce autophagy-mediated death of cancer cells (PMID:29368982), blocks NF-κB signaling to impose G0/G1 arrest (PMID:35173535), and antagonizes the MAPK-c-Myc growth program (PMID:38574733), collectively acting as a tumor suppressor whose loss promotes proliferation in renal, oral, and other epithelial cancers (PMID:32161311, PMID:40644959). In neurons, DIRAS2 suppresses ERK/p38 MAPK signaling to inhibit ferroptosis and thereby maintain excitation/inhibition balance (PMID:41880562).

1. 2015 High

   Established the first biochemical handle on DIRAS2 regulation by showing its abundance and nucleotide state are controlled by a stable binding partner rather than canonical GEF/GAP cycling.

   Evidence Co-purification from rat brain cytosol, size-exclusion chromatography with recombinant proteins, and pulse-chase CAAX-dependent binding assays

   PMID:26149690

   Open questions at the time

   • Does not establish the active GTP-bound effector functions of DIRAS2
   • Functional consequence of SmgGDS-mediated stabilization for downstream signaling untested
2. 2018 Medium

   Placed DIRAS2 in cancer biology by demonstrating it acts as a tumor suppressor that inhibits two major proliferative pathways and engages autophagy transcription factors.

   Evidence Re-expression gain-of-function in ovarian cancer cell lines with autophagy assays, AKT1-MTOR/RAS-MAPK pathway readouts, and FOXO3/TFEB nuclear localization analysis

   PMID:29368982

   Open questions at the time

   • Direct biochemical link between DIRAS2 and pathway components not reconstituted
   • Whether DIRAS2 acts on FOXO3/TFEB directly or via MAPK/AKT suppression unresolved
3. 2020 Medium

   Identified pVHL as both an E3 ligase that degrades DIRAS2 and a context determinant, revealing DIRAS2 can switch to a proliferation-promoting RAS/MAPK activator when VHL is lost.

   Evidence Gain/loss-of-function in ccRCC cell lines, MAPK phosphorylation assays, reciprocal Co-IP with pVHL, and ubiquitination assays

   PMID:32161311

   Open questions at the time

   • Mechanism of the tumor-suppressor-to-oncogene context switch not defined
   • Direct ubiquitin transfer by pVHL to DIRAS2 lysines not mapped
4. 2022 Medium

   Extended DIRAS2 growth suppression to NF-κB-driven cell-cycle control and identified PSMD2-coupled proteasomal degradation as a turnover route.

   Evidence Overexpression/knockdown in CRC cell lines, cell-cycle analysis, NF-κB reporter assays, Co-IP with PSMD2, and proteasome inhibitor rescue

   PMID:35173535

   Open questions at the time

   • How DIRAS2 mechanistically blocks NF-κB not defined
   • Whether PSMD2 binding is direct or bridged by an E3 ligase unclear
5. 2024 High

   Defined a specific E3 ligase pathway for DIRAS2 turnover and demonstrated in vivo, via genetic epistasis, that DIRAS2 stabilization mediates growth suppression.

   Evidence Ube2f deletion in a KrasG12D mouse PDAC model, ubiquitylation assays identifying DIRAS2 as a CRL5ASB11 substrate, Diras2-deletion rescue epistasis, and MAPK-c-Myc analysis

   PMID:38574733

   Open questions at the time

   • ASB11 substrate-recognition determinants on DIRAS2 not mapped
   • Relationship between CRL5ASB11, pVHL, and PSMD2 degradation routes not integrated
6. 2021 Medium

   Connected DIRAS2 epigenetic silencing to chemoresistance, showing promoter heterochromatinization restrains DIRAS2 and HDAC inhibition restores it.

   Evidence Overexpression in glioblastoma lines with lomustine sensitivity and DNA-damage marker assays, promoter histone modification analysis, and HDAC inhibitor re-expression

   PMID:34680261

   Open questions at the time

   • Direct role of DIRAS2 in p53-dependent damage response not established
   • Specific histone marks and writers/erasers at the promoter not identified
7. 2025 Medium

   Identified a signaling axis that suppresses DIRAS2 expression, linking tumor microenvironment cytokine signaling to loss of its tumor-suppressor function.

   Evidence TAM/TNBC co-culture, cytokine arrays, proteomics, CRISPR-Cas9 knockout, and STAT3 activation/DIRAS2 expression assays after eNAMPT/CCR5 intervention

   PMID:40083697

   Open questions at the time

   • Whether STAT3 directly represses the DIRAS2 promoter not shown
   • Downstream effectors of DIRAS2 loss in stemness/macrophage recruitment not dissected
8. 2025 Medium

   Provided in vivo genetic evidence that DIRAS2 drives epithelial proliferation through the RAF/MEK/MAPK cascade in precancerous lesions.

   Evidence Conditional epithelial knockout mice (K14-Cre x DIRAS2flox/flox) in a 4NQO precancer model, human dysplastic keratinocyte knockdown, and MAPK protein readouts

   PMID:40644959

   Open questions at the time

   • Reconciliation of pro-proliferative MAPK activation here versus MAPK suppression elsewhere unresolved
   • Direct biochemical engagement of RAF/MEK by DIRAS2 not shown
9. 2026 High

   Established a neuronal function for DIRAS2, placing it upstream of ferroptosis via ERK/p38 MAPK suppression to control excitation/inhibition balance.

   Evidence In vivo and in vitro overexpression/knockdown in a kainic acid epilepsy model, whole-cell patch-clamp, quantitative proteomics, ferroptosis assays, and ferrostatin-1 epistasis rescue

   PMID:41880562

   Open questions at the time

   • Molecular mechanism by which DIRAS2 inhibits ERK/p38 not defined
   • Link between SmgGDS-regulated nucleotide state and neuronal MAPK suppression untested
10. 2019 Low

    Suggested a broader neurodevelopmental transcriptional role for DIRAS2, linking it to ADHD genetics.

    Evidence shRNA knockdown in murine hippocampal primary cells with microarray profiling, qPCR validation, and ADHD GWAS gene-set enrichment

    PMID:30623719

    Open questions at the time

    • Transcriptomic profiling without protein-level mechanistic follow-up
    • Direct targets and signaling intermediaries between DIRAS2 and the altered genes unknown

• It remains unresolved how DIRAS2 toggles between tumor-suppressive MAPK inhibition and proliferation-promoting MAPK activation across tissue contexts, and what GTP-loaded effectors transmit its signal.
• No direct effector of GTP-bound DIRAS2 identified
• Context determinants of opposite MAPK outputs not mechanistically defined
• Integration of multiple degradation pathways (CRL5ASB11, pVHL, PSMD2) not unified